Regent Peak Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Regent Peak Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	684
2020 Q4	$0	Buy	+1	New	+$258	﹤0.01%	1103

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Regent Peak Wealth Advisors's NKTR Position: Q1 2021 in Review

Regent Peak Wealth Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 1 share.

Regent Peak Wealth Advisors first reported a position in NKTR in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 236 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

Regent Peak Wealth Advisors reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
Regent Peak Wealth Advisors sold 1 Nektar Therapeutics share in Q1 2021.
Regent Peak Wealth Advisors first reported a position in Nektar Therapeutics in Q4 2020 and held it in 1 quarter.
Regent Peak Wealth Advisors's Nektar Therapeutics position peaked at $0 in Q4 2020.
236 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on Regent Peak Wealth Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.